Based on seminal randomized controlled trials (RCTs) (1), EGFR TKIs are the first-line treatment of choice in patients with advanced EGFR mutation-positive (EGFRm+) NSCLC, with five TKIs currently approved. Here, EGFR is linked to non-small cell lung carcinoma.